Portfolio Finder

4 Animals AlsterScience

4 Animals AlsterScience GmbH develops innovative therapies for animals. Through targeted use of natural immunomodulators immune function is significantly improved and in sick and old animals optimally restored.

HTGF-Manager: Ulrike Kalapis
In portfolio 03. Jul 2014 – 09. Dec 2020

Abalos

Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells. Through viral replication within cancer cells, Abalos’ arenavirus-based drug candidates are designed to awake precise innate and adaptive immune responses and activate all relevant immune cell types against primary tumors and metastases. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos’ goal is to achieve a quantum leap in immuno-oncology.

HTGF-Manager: Dr. Frank Hensel
Added to portfolio 10. Jul 2019

adivo

adivo is a biotech company generating therapeutic antibodies for companion animals, addressing the medical needs in dogs, with an upside potential for a future in care for other species.
Antibody selection is based on a novel fully synthetic, dog-specific phage display library that allows de-novo identification of antibodies to select a drug candidate with optimal properties.
adivo is a spin-off from MorphoSys AG, a leading European biopharmaceutical company. The team transfers an in-depth expertise in discovery and development of human therapeutic antibodies to the veterinary market.

HTGF-Manager: Dr. Lena Krzyzak
Added to portfolio 19. Jul 2018

AdvanceCOR

AdvanceCOR is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative biological drugs in indications with unmet medical needs.

HTGF-Manager: Marco Winzer
Added to portfolio 25. Jun 2014

Alentis

Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (hepatocellular carcinoma, HCC).

Alentis has in-licensed platform technologies and monoclonal antibodies which are the result of more than a decade of research from the University of Strasbourg and Inserm, the French National Institutes of Health and the Mount Sinai Hospital, New York.

The portfolio is based on profound knowledge and expertise in liver disease, unique patient-derived model systems and the discovery of a novel, very fundamental mechanism of action underlying these diseases.

Alentis has lead monoclonal antibodies which show consistent compelling efficacy and safety in patient-derived cell and animal models.

Furthermore, Alentis has a proprietary discovery platform enabling fast-track discovery and development of compounds and targets that are relevant in the pathology of late stage liver disease and carcinogenesis.

Website: alentis.ch
HTGF-Manager: Dr. Frank Hensel
Added to portfolio 12. Apr 2019

ALGIAX

Algiax Pharmaceuticals is a young, innovative research company in the field of neurological diseases with a special focus on neuropathic pain.

HTGF-Manager: Dr. Martin Pfister
Added to portfolio 13. Jan 2012

Atriva

Atriva Therapeutics stands for the next generation of antiviral therapies. MEK Inhibitors have high potential as truly efficacious and safe antiviral drugs to address the urgent need e.g. for a novel, broadly active influenza therapy.

HTGF-Manager: Dr. Frank Hensel
Added to portfolio 27. Dec 2016

AudioCure

AudioCure Pharma specializes in the preclinical and clinical development of small molecules for the treatment of audiological and neurodegenerative diseases like sudden hearing loss, tinnitus, Parkinson’s and Alzheimer’s disease. In a first step the company focuses on sudden hearing loss.

Our compounds AC102 and AC002 have shown excellent efficacy in different animal models for the above-mentioned indications. Consequently, AudioCure is on its way to perform formal preclinical tests and to move AC102 into first-in-man testing.

HTGF-Manager: Dr. Martin Pfister
Added to portfolio 20. Apr 2012

CARDIOR

Cardior is focused on the development and clinical validation of ncRNA therapeutics for patients with myocardial infarction and heart failure. Cardior aims to market its products in collaboration with a strategic pharma partner after clinical proof-of-concept (POC) data.

HTGF-Manager: Dr. Lena Krzyzak
Added to portfolio 03. May 2017

Draupnir Bio

Draupnir Bio is founded on the pillars of outstanding protein and carbohydrate chemistry. Its mission is to understand the molecular basis of how disease-risk proteins interact with carbohydrate structures of the vascular glycocalyx, and use this knowledge to develop therapeutics for life-threatening illnesses. The company is a spin out from Aarhus University, Denmark and Max Planck Institute, Potsdam, Germany.
The lead program is a small molecule oral available PCSK9 inhibitor for lowering LDL cholesterol. Its discovery is based on the finding that PCSK9-induced degradation of the LDL receptor requires the interaction of PCSK9 with distinct heparan sulfate structures of the liver glycocalyx. Inhibition of the PCSK9/heparan sulfate interaction protects the LDL receptor and allows it to remove LDL cholesterol from the blood, thereby preventing the progression of ischemic heart disease, the biggest killer worldwide.

HTGF-Manager: Dr. Lena Krzyzak
Added to portfolio 27. Dec 2018

Emergence Therapeutics

Development of antibody conjugate-based cancer therapeutics for solid tumors with high unmet needs that are otherwise difficult to treat
Problem: Solid cancers are still very difficult to treat. Most treatments increase life expectancy, but only a few lead to a complete cure. Antibody drug conjugates (ADCs) have proven to be a promising therapeutic approach, but still cause significant and toxic side effects.

The solution: Emergence Therapeutics has identified several areas where ADCs can be improved. These are the antibody itself, the toxin used to kill the cancer cell, and the linker that couples the toxin to the antibody.

Technology/ IP: The antibody-related IP is in-licensed from the University of Aix-Marseille (France) and the toxin-related IP is in-licensed from Heidelberg Pharma.
The IP and all results generated for the ADC in development will be out-licensed or sold by Emergence.

HTGF-Manager: Dr. Anke Caßing
Added to portfolio 26. Nov 2019

FundaMental Pharma

FundaMental Pharma GmbH (FMP) is developing new types of drugs that act as ‘molecular spacers’ and disrupt a death signaling complex in the brain. Using this pharmacological strategy, FMP scientists succeeded in eliminating the toxic properties of the glutamate-controlled NMDA-type neurotransmitter receptor.

FMP has already identified first drug candidates that are currently in pre-clinical development and will be tested in humans within the next 2-3 years.

The discovery of an entirely new pharmacological principle ('interface targeting') raises hopes that previously untreatable neurodegenerative diseases in humans can be mitigated. Interface inhibitors open up new possibilities, both in terms of drug treatments and gene therapy approaches.

FMP was established in 2016 as a biotech start-up of the Interdisciplinary Center for Neurosciences (IZN) at Heidelberg University by Professor Hilmar Bading, Junior Professor Daniela Mauceri and Dr. Thomas Schulze.

HTGF-Manager: Niels Sharman
Added to portfolio 04. May 2021

HepaRegeniX

Since its operational start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular target Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4). A first compound has recently started clinical development.
MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers. This new and unique therapeutic concept for the treatment of liver diseases was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany. Investors in HepaRegeniX include the Boehringer Ingelheim Venture Fund (BIVF), Novo Holdings A/S, Coparion, High-Tech Gruenderfonds and Ascenion GmbH.

HTGF-Manager: Dr. Frank Hensel
Added to portfolio 14. Nov 2016

Immunic

Immunic Therapeutics is a clinical-stage biotech company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Immunic, Inc. is headquartered in New York. Its subsidiary, Immunic AG, is based in Graefelfing near Munich, Germany, where the company’s research and development activities are conducted. Additional subsidiaries are located in Halle/Saale, Germany, and Melbourne, Australia.

Immunic is developing three small molecule products: lead development program, IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. IMU-838 is in phase 2 clinical development for COVID-19, relapsing-remitting multiple sclerosis, ulcerative colitis and, in collaboration with the Mayo Clinic, primary sclerosing cholangitis.

HTGF-Manager: Dr. Lena Krzyzak
Added to portfolio 10. Aug 2016

Immunservice

Immunservice GmbH develops biomimetic immune hormones, in particular interleukin-2, for safer, more effective and potentially curative therapies, especially in cancer.

HTGF-Manager: Ulrike Kalapis
Added to portfolio 20. Jul 2007

innerspace

Innerspace develops novel, psychologically based training solutions for highly critical applications in the life science industry. Cleanroom operators are comprehensively prepared for the key moments of their work using the DeepTraining approach, implemented in virtual reality. With regular practice in virtual space, they can safely deepen their behaviour patterns and their understanding of production in critical areas of activity. Since company foundation Innerspace has positioned itself clearly as the innovator combining content and VR-technology in the Edu-Tech-Market. Innerspace already sells its products to numerous leading international pharma companies.

HTGF-Manager: Tobias Faupel
Added to portfolio 21. Nov 2019

Lipocalyx

Lipocalyx develops transfection reagents. Our Viromers® are polymers emulating a viral mechanism for cell entry. The company provides reagents and currently establishes services for pharmaceutical applications.

HTGF-Manager: Ulrike Kalapis
In portfolio 14. Jul 2011 – 07. Apr 2021

MYR (Exit)

MYR develops a novel, peptide-based, first-in-class drug (entry inhibitor) for the treatment of chronic hepatitis B and Delta infections. Clinical phase IIb currently in preparation.

HTGF-Manager: Dr. Bernd Goergen
In portfolio 21. Jan 2011 – 09. Dec 2020

OMEICOS

OMEICOS Therapeutics develops a novel, first-in-class, small molecule drug addressing a new Mode of Action for the treatment and prevention of atrial fibrillation.

HTGF-Manager: Dr. Martin Pfister
Added to portfolio 17. Sep 2013

Pantherna Therapeutics

Pantherna Therapeutics is a privately-held biopharmaceutical company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA drugs in the endothelium. Pantherna is based in Hennigsdorf (Brandenburg) close to Berlin, Germany.

HTGF-Manager: Dr. Anke Caßing
Added to portfolio 27. May 2019

PerformaNat

PerformaNat GmbH was founded in 2015 as a spin-off of the veterinary medicine department of the Freie Universität Berlin. The first product – an animal-feed additive for use with dairy cows – was developed with the help of the EXIST Transfer of Research Grant Program of the German Federal Ministry for Economic Affairs and Energy, and it has already been successfully out-licenced. Further products are being developed.

Perora

Perora develops a polymer-based fat-binding medical device as a novel platform for weight management and the treatment of obesity.

HTGF-Manager: Marco Winzer
Added to portfolio 03. Jun 2013

SciRhom

SciRhom GmbH is a therapeutic antibody company developing first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. Based on a decade of cutting-edge bench research and the completion of a challenging, yet ultimately successful antibody campaign, SciRhom is now in the unique position to pursue the development of monoclonal antibodies against iRhom2 for the treatment of major autoimmune diseases.

Website: scirhom.com
HTGF-Manager: Dr. Frank Hensel
Added to portfolio 27. Oct 2016

SIRION Biotech

SIRION BIOTECH produces genetically modified cells and is technology provider in the area of viral vector systems. The specialist in RNAi technology distributes more than 100 products and services. A goal is to develop optimized cell systems for the optimized vaccine, antibody or protein production

HTGF-Manager: Marco Winzer
In portfolio 04. Sep 2007 – 22. Jun 2021

Synendos Therapeuthics

Synendos is developing first-in-class inhibitors that modulate a newly identified drug target in the body’s endocannabinoid system, enabling restoration of endogenous cannabinoid levels that are suppressed in certain pathological conditions. The endocannabinoid system is a key neuromodulator system in the CNS involved in regulating various physiological and cognitive processes. Synendos’ newly developed selective endocannabinoid reuptake inhibitors (SERIs) act by increasing the levels of endogenous cannabinoids in a self-limiting mode of action, representing an innovative and potentially safer therapeutic approach to CNS disorders associated with anxiety, mood and stress-related disorders.

HTGF-Manager: Dr. Fabian Mohr
Added to portfolio 31. Oct 2020

Tacalyx

Tacalyx researches and develops therapeutics targeting TACAs (tumor-associated carbohydrate antigens). These strongly tumor-specific structures are synthesized by cancer cells and contribute significantly to its virulence and metastasis. The recent possibility of synthesizing these complex structures allows the production of specific antibodies for the treatment of currently unsatisfactorily treatable cancers.

Website: tacalyx.com
HTGF-Manager: Dr. Lena Krzyzak
Added to portfolio 02. Jul 2019

Thermosome

Thermosome develops novel drugs for locally-advanced solid tumors by using nanocarriers for heat-induced local drug delivery and thereby reaches up to 15 fold higher local drug concentrations.

HTGF-Manager: Dr. Caroline Fichtner
Added to portfolio 15. Oct 2015

TolerogenixX

TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences.

HTGF-Manager: Ulrike Kalapis
Added to portfolio 21. Dec 2016

Tubulis

Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. Employing the company’s proprietary ADC development approach, Tubulis will advance a variety of conjugates, unlimited by indication

HTGF-Manager: Dr. Lena Krzyzak
Added to portfolio 17. Jul 2020

Zedira

Zedira is a clinical stage biotech company specialized in the enzyme class of transglutaminases. Zedira performs drug discovery (e.g. celiac disease, diabetic nephropathy and thromboprophylaxis) and markets specialty reagents for R&D and diagnostics.

Website: zedira.com
HTGF-Manager: Marco Winzer
Added to portfolio 03. Sep 2007